ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, a specific inhibitor that targets the BH3 domain involved in HSP70-BIM interaction has been shown to disrupt this association and thereby overcome the BCR-ABL independent TKI resistance in CML [145].